D. Pauw, B. Walsh, T. Donnelly, J. Stevens, D. Edwards et al., Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clinical Infectious Diseases, vol.285, issue.12, pp.1813-1834, 2008.
DOI : 10.1086/518852

S. Herman, R. Mustafa, J. Gyamfi, S. Pittaluga, S. Chang et al., Ibrutinib inhibits BCR and NF-?B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

, Blood, vol.123, issue.21, pp.3286-95, 2014.

O. Lortholary, J. Gangneux, K. Sitbon, B. Lebeau, F. De-monbrison et al.,

, Epidemiological trends in invasive aspergillosis in France: the SAIF network, Clin Microbiol Infect, vol.17, issue.12, pp.1882-1891, 2005.

R. Ruchlemer, B. Ami, R. Lachish, and T. , Ibrutinib for Chronic Lymphocytic Leukemia, N Engl J Med, vol.374, issue.16, pp.1593-1597, 2016.

M. Baron, J. Zini, C. Belval, T. Vignon, M. Denis et al., Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis, Leukemia & Lymphoma, vol.2016, issue.12, pp.2981-2982, 2017.
DOI : 10.1038/361226a0

URL : https://hal.archives-ouvertes.fr/pasteur-01851918

R. Herbrecht, D. Denning, T. Patterson, J. Bennett, R. Greene et al.,

, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, vol.347, issue.6, pp.408-423, 2002.

J. Byrd, J. Brown, O. Brien, S. Barrientos, J. Kay et al., Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.371, issue.3, pp.213-236, 2014.
DOI : 10.1056/NEJMoa1400376